Global drugmakers hope to increase their share in Russian public procurements this year

23 September 2019

Global pharmaceutical companies hope to increase their share of public procurements in Russia as soon as this year, thanks to the new methodology on the formation of the initial maximum price for state contracts, which has been recently introduced by the Russian Ministry of Health, reports The Pharma Letter’s local correspondent.

According to data from the Russian analyst agency DSM Group, at present the share of foreigners in drugs’ public procurements in Russia is estimated at about 33%, which is significantly higher than the figures of some previous years.

More than 25% of all auctions declared invalid

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK